The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today released a new Weight Loss Medications ...
The NHS spending watchdog said about 220,000 people could benefit from the drug in an initial three-year period ...